{
    "organizations": [],
    "uuid": "1bad50ef9ec93b5dff2fc90f641b54e0ba98b674",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biodelivery-sciences-announces-bel/brief-biodelivery-sciences-announces-belbuca-patent-litigation-settlement-agreement-with-teva-idUSFWN1PW0MP",
    "ord_in_thread": 0,
    "title": "BRIEF-Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Biodelivery Sciences International Inc :\n* BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA\n* BIODELIVERY SCIENCES - ENTERED INTO SETTLEMENT AGREEMENT WITH TEVA PHARMACEUTICALS USA, INC. AND TEVA PHARMACEUTICALS INDUSTRIES, LTD.\n* BIODELIVERY SCIENCES - AGREEMENT RESOLVES BELBUCA (BUPRENORPHINE) BUCCAL FILM (CIII), PATENT LITIGATION AGAINST TEVA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T20:08:00.000+02:00",
    "crawled": "2018-02-07T22:23:05.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "biodelivery",
        "science",
        "international",
        "inc",
        "biodelivery",
        "science",
        "announces",
        "belbuca",
        "patent",
        "litigation",
        "settlement",
        "agreement",
        "teva",
        "biodelivery",
        "science",
        "entered",
        "settlement",
        "agreement",
        "teva",
        "pharmaceutical",
        "usa",
        "teva",
        "pharmaceutical",
        "industry",
        "biodelivery",
        "science",
        "agreement",
        "resolve",
        "belbuca",
        "buprenorphine",
        "buccal",
        "film",
        "ciii",
        "patent",
        "litigation",
        "teva",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}